

CRITICAL OUTCOME'S LEAD CANCER DRUG CANDIDATE, COTI-2, RECEIVES SIXTH U.S. PATENT AND FIRST JAPANESE PATENT

Additional patents further enhance the value of COTI-2

London, Ontario (October 3, 2014): Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX Venture: COT; OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, is pleased to announce that COTI-2, the Company's lead oncology asset, has received additional patent protection. The United States ("U.S.") Patent and Trademark Office has granted its sixth patent and the Japan Patent Office has granted its first patent for the Company's lead oncology asset.

"We continue to pursue intellectual property coverage for COTI-2 and these recent patent grants strengthen our overall IP position," said Dr. Wayne Danter, President and CEO of COTI. "In addition to the sixth U.S. patent and our first Japanese patent, we have several other patents pending for COTI-2 in major international markets. The continued development of our patent portfolio supports our ability to broadly protect our lead oncology asset, and reinforces our potential to maximize future commercial licensing opportunities."

Newly issued patents

U.S. Patent No. 8,822,475 extends and enhances the methods of treating cancers using compounds in the COTI-2 family covered under previous patent grants. Issuance of this patent strengthens the value of the COTI-2 franchise for licensing in the U.S. market.

Japanese Patent No. 5571387 covers the COTI-2 family of compounds, pharmaceutical preparations containing COTI-2, and methods of manufacturing the compounds. This subject matter has previously been covered in patents received in the U.S. Issuance of the Japanese patent provides the Company with additional licensing opportunities for the COTI-2 franchise in Japanese and Asian markets.

About Critical Outcome Technologies Inc.

COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules – dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com or contact:

Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO

Heisler Communications
Trevor Heisler
Investor Relations

Tel: 519-858-5157

Email: wdanter@criticaloutcome.com

Tel: 416-500-8061

Email: trevor@heislercommunications.com

Follow @CriticalOutcome on Twitter at <http://twitter.com/CriticalOutcome>

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.